Jakob Dynnes Hansen
Finanzdirektor/CFO bei ASARINA PHARMA AB
Aktive Positionen von Jakob Dynnes Hansen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ASARINA PHARMA AB | Finanzdirektor/CFO | 01.04.2017 | - |
NANEXA AB | Direktor/Vorstandsmitglied | 01.01.2023 | - |
Independent Dir/Board Member | 01.01.2023 | - | |
Zerion Pharma A/S | Finanzdirektor/CFO | - | - |
Karriereverlauf von Jakob Dynnes Hansen
Ehemalige bekannte Positionen von Jakob Dynnes Hansen
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GALECTO, INC. | Unternehmenssekretär | - | 01.04.2020 |
EVOLVA HOLDING SA | Finanzdirektor/CFO | 15.12.2009 | 31.12.2016 |
Allylix, Inc.
Allylix, Inc. Pharmaceuticals: OtherHealth Technology Allylix, Inc. develops terpene products for flavor and fragrance, food ingredients, pharmaceuticals, agricultural, and biofuels markets. The company was founded by Joseph Chappel, Thomas E. Jurgensen, and Joseph Noel on January 4, 2005 and is headquartered in Lexington, KY. | Direktor/Vorstandsmitglied | - | - |
Finanzdirektor/CFO | - | - | |
Unibank (Denmark) | Finanzdirektor/CFO | 28.12.2010 | - |
Forschungsdirektor - Fxd Inc | - | 28.12.2010 | |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Finanzdirektor/CFO | 01.09.2007 | - |
NOVO NORDISK A/S | Corporate Officer/Principal | - | - |
░░░░░░░ ░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
░░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
Ausbildung von Jakob Dynnes Hansen
University of Copenhagen | Graduate Degree |
INSEAD | Masters Business Admin |
Statistik
International
Dänemark | 7 |
Schweiz | 3 |
Vereinigte Staaten | 3 |
Operativ
Director of Finance/CFO | 8 |
Director/Board Member | 2 |
Graduate Degree | 1 |
Sektoral
Health Technology | 8 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
ZEALAND PHARMA A/S | Health Technology |
NOVO NORDISK A/S | Health Technology |
EVOLVA HOLDING SA | Consumer Non-Durables |
ASARINA PHARMA AB | Health Technology |
GALECTO, INC. | Health Technology |
NANEXA AB | Health Technology |
Private Unternehmen | 5 |
---|---|
Nuevolution AB
Nuevolution AB Pharmaceuticals: MajorHealth Technology Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark. | Health Technology |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
Unibank (Denmark) | Finance |
Allylix, Inc.
Allylix, Inc. Pharmaceuticals: OtherHealth Technology Allylix, Inc. develops terpene products for flavor and fragrance, food ingredients, pharmaceuticals, agricultural, and biofuels markets. The company was founded by Joseph Chappel, Thomas E. Jurgensen, and Joseph Noel on January 4, 2005 and is headquartered in Lexington, KY. | Health Technology |
Zerion Pharma A/S |
- Börse
- Insiders
- Jakob Dynnes Hansen
- Erfahrung